Skip to main content

Table 1 Baseline characteristics of inflammatory bowel disease (ulcerative colitis and Crohn’s disease) patients and controls

From: Susceptibility role of soluble HLA-G and HLA-G 14-bp insertion/deletion polymorphism in inflammatory bowel disease

Characteristicsa

UC (N = 50)

CD (N = 50)

Controls (N = 100)

p

Age

31.5 ± 10.1

30.5 ± 9.7

31.2 ± 9.8

0.864

Gender

   

0.990

 Male

28 (56.0)

28 (56.0)

57 (57.0)

 

 Female

22 (44.0)

22 (44.0)

43 (43.0)

 

Cigarette-smokers

40 (80.0)

35 (70.0)

39 (39.0%)

< 0.001

Disease duration (years)

   

0.314

 ≤ 3

20 (40.0)

25 (50.0)

NA

 

 > 3

30 (60.0)

25 (50.0)

NA

 

Positive family history

7 (14.0)

8 (16.0)

NA

0.779

Hb (mg/dL)

11.0 ± 3.0

10.5 ± 3.5

NA

0.682

WBC (× 109/L)

8.1 ± 3.6

7.7 ± 3.1

NA

0.783

ESR (mm/hour)

54.3 ± 22.5

58.8 ± 42.4

NA

0.876

Disease extension

    

 Ulcerative proctitis

20 (40.0)

NA

NA

 

 Left-sided colitis

15 (30.0)

NA

NA

 

 Extensive colitis

15 (30.0)

NA

NA

 

 Ileocecal

NA

43 (86.0)

NA

 

 Ileo-colonic

NA

7 (14.0)

NA

 

Symptoms

    

 Abdominal/or colon pain

33 (66.0)

33 (66.0)

NA

1.000

 Diarrhea

29 (58.0)

27 (54.0)

NA

0.840

 Fever

22 (44.0)

27 (54.0)

NA

0.424

Extra-intestinal manifestations

    

 Aphthous ulcer

9 (18.0)

15 (30.0)

NA

0.241

 Arthralgia

34 (68.0)

38 (72.0)

NA

0.504

 Skin ulcer

7 (14.0)

3 (6.0)

NA

0.318

 Appendectomy

6 (12.0)

7 (14.0)

NA

1.000

 Bowel stricture

4 (8.0)

3 (6.0)

NA

1.000

 Colostomy

5 (10.0)

6 (12.0)

NA

1.000

 Fistula

10 (20.0)

6 (12.0)

NA

0.414

 Hemorrhoids

6 (12.0)

3 (6.0)

NA

0.487

Medication

   

0.556

 Protocol A

14 (28.0)

12 (24.0)

  

 Protocol B

12 (24.0)

8 (16.0)

  

 Protocol C

11 (22.0)

11 (22.0)

  

 Protocol D

13 (26.0)

19 (38.0)

  

Adalimumab or infliximab doses

   

0.614

 0

12 (24.0)

8 (16.0)

  

 1–10

20 (40.0)

18 (36.0)

  

 11–20

13 (26.0)

18 (36.0)

  

 21–30

5 (10.0)

6 (12.0)

  
  1. aData are either mean ± standard deviation or absolute number followed by percentage in parentheses: UC ulcerative colitis, CD Crohn’s disease, Hb hemoglobin, WBC white blood cell, ESR erythrocyte sedimentation rate, protocol A anti-inflammatory and immunosuppressive, protocol B anti-inflammatory and antibiotics, protocol C anti-inflammatory, immunosuppressive and antibiotics, protocol D immunosuppressive only. p LSD (least significant), Pearson’s chi-squared or Fisher’s exact test probability, NA not applicable. Significant p is bold-marked